Highlights
– ARBs have superior evidence for slowing progression of proteinuric chronic kidney disease, particularly in patients with diabetes; they reduce albuminuria and delay renal deterioration beyond blood-pressure lowering alone (RENAAL, IDNT, KDIGO recommendations). (Refs: RENAAL, IDNT, KDIGO.)
– Dihydropyridine CCBs (e.g., amlodipine) are effective antihypertensives with robust stroke prevention and are often useful for ischemic chest pain; some data suggest comparable or better prevention of myocardial infarction in specific comparisons, but results vary by trial and population.
